Sign inJoin waitlistJoin the waitlist

Sikander Ailawadhi

Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present

University at Buffalo School of Medicine
2004–2006
Medical Microbiology University College of Medical Sciences
2003–2004
University at Buffalo School of Medicine
2000–2003
UNIV COLL OF MED SCIENCES, NEW DELHI, DELHI
1996–2000

Research

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine · 2023 · 653 citations
IAP antagonists induce anti-tumor immunity in multiple myeloma
Nature Medicine · 2016 · 150 citations
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Journal of Hematology & Oncology · 2023 · 128 citations

Asher Chanan-Khan
89 papers
Vivek Roy
58 papers
Taimur Sher
57 papers · 7 as a resident
Ricardo Parrondo
45 papers · 13 as a fellow
Prashant Kapoor
42 papers
Shaji Kumar
39 papers
Morie Gertz
38 papers
Rafael Fonseca
32 papers
Leif Bergsagel
30 papers
YL
Yi Lin
30 papers
Angela Dispenzieri
29 papers
SR
Sundararajan Rajkumar
28 papers

Clinical trials

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Principal investigator · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2031
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2028
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Principal investigator · Terminated · Phase 2
Mayo Clinic
2020–2025
Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in Clinical Trials in Minority Patient Populations: Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients
Principal investigator · Terminated
Mayo Clinic
2019–2022